Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, plcKNSA · Entity 1954 | CHIEF ACCOUNTING OFFICER | July 15, 2026 | September 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Kiniksa Pharmaceuticals International, plc
Report date July 15, 2026 · Filed September 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Ordinary ShareSEC Table I · non-derivative | Direct | 29,062 |
Ending reported balance
After 2026-09-03 transaction · row 7
7 source rows · reconciled sequenceRow 1 · 2026-07-15 · Grant · Acquired 279 · Balance 27,697 F1: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2026 to July 15, 2026. The acquisition of these shares was exempt pursuant to Rule 16b-3(e). Row 2 · 2026-09-01 · Exercise / conversion · Acquired 3,932 · Balance 31,629 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 3 · 2026-09-01 · Exercise / conversion · Acquired 2,558 · Balance 34,187 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 4 · 2026-09-01 · Exercise / conversion · Acquired 2,362 · Balance 36,549 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 5 · 2026-09-01 · Exercise / conversion · Acquired 2,644 · Balance 39,193 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. Row 6 · 2026-09-01 · Tax withholding · Disposed 5,531 · Balance 33,662 Row 7 · 2026-09-03 · Sale · Disposed 4,600 · Balance 29,062 F3: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 3,650 |
Reported balance
After 2026-09-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-09-01 · Grant · Acquired 3,650 · Balance 3,650 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2026. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 7,931 |
Reported balance
After 2026-09-01 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2026-09-01 · Exercise / conversion · Disposed 2,644 · Balance 7,931 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 4,725 |
Reported balance
After 2026-09-01 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2026-09-01 · Exercise / conversion · Disposed 2,362 · Balance 4,725 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, September 1, 2024. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 2,557 |
Reported balance
After 2026-09-01 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-09-01 · Exercise / conversion · Disposed 2,558 · Balance 2,557 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F8: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-09-01 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2026-09-01 · Exercise / conversion · Disposed 3,932 · Balance 0 F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer. F9: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. |
| Share OptionSEC Table II · derivative / convertible security · Conversion / exercise price $79.28 · Expires 2036-08-31 | Direct | 14,600 |
Reported balance
After 2026-09-01 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2026-09-01 · Grant · Acquired 14,600 · Balance 14,600 F5: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2026 to July 15, 2026. The acquisition of these shares was exempt pursuant to Rule 16b-3(e).
F2: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer.
F3: This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on May 24, 2025.
F4: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2026.
F5: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026.
F6: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025.
F7: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date, September 1, 2024.
F8: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023.
F9: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2023 Filed Apr 3, 2023 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 20,459 | $0.00 Strike: $10.76 | $0.00 |
DisclosureSEC source: 0001415889-23-005790 · form4-04032023_040420.xml · derivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,459 Underlying: Class A Common Share · 20,459 shares Expires 2033-03-31 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2023. Read SEC document |
| March 20, 2023 Filed Mar 20, 2023 21:18 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 2,163 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-005234 · form4-03202023_090305.xml · derivative · entry 7 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Share · 2,163 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F4 · derivative.exercise_date: The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2023; there was no expiration date for the RSUs. F4 · derivative.expiration_date: The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2023; there was no expiration date for the RSUs. Read SEC document |
| March 20, 2023 Filed Mar 20, 2023 21:18 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 635 | $11.12 | $7,061.20 |
DisclosureSEC source: 0001415889-23-005234 · form4-03202023_090305.xml · nonDerivative · entry 5 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,199 Read SEC document |
| March 20, 2023 Filed Mar 20, 2023 21:18 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 2,163 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-005234 · form4-03202023_090305.xml · nonDerivative · entry 4 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,834 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 21:18 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 774 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-005234 · form4-03202023_090305.xml · derivative · entry 6 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,549 Underlying: Class A Common Share · 774 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each anniversary of the date of grant, March 16, 2021. F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each anniversary of the date of grant, March 16, 2021. Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 21:18 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 221 | $11.46 | $2,532.66 |
DisclosureSEC source: 0001415889-23-005234 · form4-03202023_090305.xml · nonDerivative · entry 3 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,671 Read SEC document |
| March 16, 2023 Filed Mar 20, 2023 21:18 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 774 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-23-005234 · form4-03202023_090305.xml · nonDerivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,892 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| January 15, 2023 Filed Mar 20, 2023 21:18 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantClass A Common Share | 704 | $9.56 | $6,730.24 |
DisclosureSEC source: 0001415889-23-005234 · form4-03202023_090305.xml · nonDerivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,118 F1 · kind: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of July 16, 2022 to January 15, 2023. The acquisition of such shares was exempt pursuant to Rule 16b-3(c). Read SEC document |
| October 04, 2022 Filed Oct 6, 2022 20:18 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 175 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-010379 · form4-10062022_011035.xml · derivative · entry 3 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 525 Underlying: Class A Common Share · 175 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each anniversary of the date of grant, October 4, 2021. F2 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each anniversary of the date of grant, October 4, 2021. Read SEC document |
| October 04, 2022 Filed Oct 6, 2022 20:18 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 52 | $14.23 | $739.96 |
DisclosureSEC source: 0001415889-22-010379 · form4-10062022_011035.xml · nonDerivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,414 Read SEC document |
| October 04, 2022 Filed Oct 6, 2022 20:18 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 175 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-010379 · form4-10062022_011035.xml · nonDerivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,466 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 20:08 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 775 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-009344 · form4-09062022_010922.xml · derivative · entry 6 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,323 Underlying: Class A Common Share · 775 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F5 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. F5 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 20:08 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 228 | $11.44 | $2,608.32 |
DisclosureSEC source: 0001415889-22-009344 · form4-09062022_010922.xml · nonDerivative · entry 3 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,291 Read SEC document |
| September 02, 2022 Filed Sep 6, 2022 20:08 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 775 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-009344 · form4-09062022_010922.xml · nonDerivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,519 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:08 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 15,730 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-009344 · form4-09062022_010922.xml · derivative · entry 5 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,730 Underlying: Class A Common Share · 15,730 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F4 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. F4 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022. Read SEC document |
| September 01, 2022 Filed Sep 6, 2022 20:08 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 31,460 | $0.00 Strike: $11.97 | $0.00 |
DisclosureSEC source: 0001415889-22-009344 · form4-09062022_010922.xml · derivative · entry 4 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,460 Underlying: Class A Common Share · 31,460 shares Expires 2032-08-31 F3 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2022. Read SEC document |
| July 15, 2022 Filed Sep 6, 2022 20:08 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantClass A Common Share | 703 | $9.56 | $6,720.68 |
DisclosureSEC source: 0001415889-22-009344 · form4-09062022_010922.xml · nonDerivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,744 F1 · kind: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 16, 2022 to July 15, 2022. The acquisition of such shares was exempt pursuant to Rule 16b-3(c). Read SEC document |
| April 07, 2022 Filed Apr 11, 2022 20:31 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Unit · Derivative | 15,730 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-003991 · form4-04112022_040411.xml · derivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,730 Underlying: Class A Common Share · 15,730 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. F3 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022. Read SEC document |
| April 07, 2022 Filed Apr 11, 2022 20:31 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 31,460 | $0.00 Strike: $11.10 | $0.00 |
DisclosureSEC source: 0001415889-22-003991 · form4-04112022_040411.xml · derivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,460 Underlying: Class A Common Share · 31,460 shares Expires 2032-04-06 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 3,231 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-003285 · form4-03232022_040321.xml · derivative · entry 3 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Share · 3,231 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2022; there was no expiration date for the RSUs. F2 · derivative.expiration_date: The performance criteria for these RSUs were met. The RSUs vested in a single installment on March 20, 2022; there was no expiration date for the RSUs. Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 1,120 | $10.98 | $12,297.60 |
DisclosureSEC source: 0001415889-22-003285 · form4-03232022_040321.xml · nonDerivative · entry 2 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,041 Read SEC document |
| March 21, 2022 Filed Mar 23, 2022 20:30 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 3,231 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-22-003285 · form4-03232022_040321.xml · nonDerivative · entry 1 Megna Michael R · CIK 0001464583 · CHIEF ACCOUNTING OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,161 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionRestricted Share Unit · Derivative | 775 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-002329 · edgar.xml · derivative · entry 7 Megna Michael R · CIK 0001464583 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,323 Underlying: Class A Common Share · 775 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F6 · derivative.exercise_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. F6 · derivative.expiration_date: The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Tax withholdingClass A Common Share | 269 | $10.13 | $2,724.97 |
DisclosureSEC source: 0001179110-22-002329 · edgar.xml · nonDerivative · entry 6 Megna Michael R · CIK 0001464583 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,930 Read SEC document |
| March 16, 2022 Filed Mar 18, 2022 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | Exercise / conversionClass A Common Share | 775 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001179110-22-002329 · edgar.xml · nonDerivative · entry 5 Megna Michael R · CIK 0001464583 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,199 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. Read SEC document |
| January 15, 2022 Filed Mar 18, 2022 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantClass A Common Share | 653 | $9.63 | $6,288.39 |
DisclosureSEC source: 0001179110-22-002329 · edgar.xml · nonDerivative · entry 4 Megna Michael R · CIK 0001464583 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,424 F4 · kind: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of July 16, 2021 to January 15, 2022. The acquisition of such shares was exempt pursuant to Rule 16b-3(c). Read SEC document |
| October 04, 2021 Filed Oct 6, 2021 20:51 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 700 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-009263 · edgar.xml · derivative · entry 1 Megna Michael R · CIK 0001464583 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 700 Underlying: Class A Common Shares · 700 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each anniversary of the date of grant, October 4, 2021. F2 · derivative.expiration_date: The RSUs vest over a four year period, with 25% of the RSUs vesting on each anniversary of the date of grant, October 4, 2021. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 3,098 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-008658 · edgar.xml · derivative · entry 2 Megna Michael R · CIK 0001464583 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,098 Underlying: Class A Common Shares · 3,098 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. F3 · derivative.expiration_date: The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021. Read SEC document |
| September 02, 2021 Filed Sep 7, 2021 21:20 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 6,195 | $0.00 Strike: $12.97 | $0.00 |
DisclosureSEC source: 0001179110-21-008658 · edgar.xml · derivative · entry 1 Megna Michael R · CIK 0001464583 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,195 Underlying: Class A Common Shares · 6,195 shares Expires 2031-09-01 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 2, 2021. Read SEC document |
| July 15, 2021 Filed Mar 18, 2022 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantClass A Common Share | 588 | $11.49 | $6,756.12 |
DisclosureSEC source: 0001179110-22-002329 · edgar.xml · nonDerivative · entry 3 Megna Michael R · CIK 0001464583 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,771 F3 · kind: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 1, 2021 to July 15, 2021. The acquisition of such shares was exempt pursuant to Rule 16b-3(c). Read SEC document |
| March 20, 2021 Filed Mar 23, 2021 21:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 2,163 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-003730 · edgar.xml · derivative · entry 2 Megna Michael R · CIK 0001464583 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,163 Underlying: Class A Common Shares · 2,163 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The performance criteria for these RSUs were met. The RSUs will vest in a single installment on March 20, 2023, subject to the Reporting Person's continuous employment with the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSUs. F3 · derivative.expiration_date: The performance criteria for these RSUs were met. The RSUs will vest in a single installment on March 20, 2023, subject to the Reporting Person's continuous employment with the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSUs. Read SEC document |
| March 20, 2021 Filed Mar 23, 2021 21:34 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 3,231 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-003730 · edgar.xml · derivative · entry 1 Megna Michael R · CIK 0001464583 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,231 Underlying: Class A Common Shares · 3,231 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Common Share of the Issuer. F2 · derivative.exercise_date: The performance criteria for these RSUs were met. The RSUs will vest in a single installment on March 20, 2022, subject to the Reporting Person's continuous employment with the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSUs. F2 · derivative.expiration_date: The performance criteria for these RSUs were met. The RSUs will vest in a single installment on March 20, 2022, subject to the Reporting Person's continuous employment with the Issuer or any of its subsidiaries on the vesting date; there is no expiration date for the RSUs. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 23:12 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantRestricted Share Units · Derivative | 3,098 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-003618 · edgar.xml · derivative · entry 2 Megna Michael R · CIK 0001464583 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,098 Underlying: Class A Common Shares · 3,098 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Share Unit represents a contingent right to receive one Class A Common Share of the Issuer. F3 · derivative.exercise_date: The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. F3 · derivative.expiration_date: The Restricted Share Units (RSUs) vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, March 16, 2021. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 23:12 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 6,195 | $0.00 Strike: $22.89 | $0.00 |
DisclosureSEC source: 0001179110-21-003618 · edgar.xml · derivative · entry 1 Megna Michael R · CIK 0001464583 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,195 Underlying: Class A Common Shares · 6,195 shares Expires 2031-03-15 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is March 16, 2021. Read SEC document |
| December 31, 2020 Filed Mar 18, 2022 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantClass A Common Share | 405 | $15.02 | $6,083.10 |
DisclosureSEC source: 0001179110-22-002329 · edgar.xml · nonDerivative · entry 2 Megna Michael R · CIK 0001464583 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,183 F2 · kind: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of July 1, 2020 to December 31, 2020. The acquisition of such shares was exempt pursuant to Rule 16b-3(c). Read SEC document |
| September 10, 2020 Filed Sep 14, 2020 21:06 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 19,000 | $0.00 Strike: $15.50 | $0.00 |
DisclosureSEC source: 0001179110-20-009719 · edgar.xml · derivative · entry 1 Megna Michael R · CIK 0001464583 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,000 Underlying: Class A Common Shares · 19,000 shares Expires 2030-09-09 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is September 10, 2020. Read SEC document |
| June 30, 2020 Filed Mar 18, 2022 20:40 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantClass A Common Share | 641 | $9.51 | $6,095.91 |
DisclosureSEC source: 0001179110-22-002329 · edgar.xml · nonDerivative · entry 1 Megna Michael R · CIK 0001464583 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,778 F1 · kind: The reporting person is voluntarily reporting the acquisition of these shares pursuant to the Issuer's 2018 Employee Share Purchase Plan for the purchase period of January 1, 2020 to June 30, 2020. The acquisition of such shares was exempt pursuant to Rule 16b-3(c). Read SEC document |
| March 13, 2020 Filed Mar 17, 2020 21:21 UTC | Kiniksa Pharmaceuticals International, plc KNSA · Entity 1954 | GrantShare Option · Derivative | 17,000 | $0.00 Strike: $15.52 | $0.00 |
DisclosureSEC source: 0001179110-20-003831 · edgar.xml · derivative · entry 1 Megna Michael R · CIK 0001464583 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Class A Common Shares · 17,000 shares Expires 2030-03-12 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in thirty-six equal monthly installments thereafter. The vesting commencement date is March 13, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.